Cargando…
Clinical validity and utility of genetic risk scores in prostate cancer
Current issues related to prostate cancer (PCa) clinical care (e.g., over-screening, over-diagnosis, and over-treatment of nonaggressive PCa) call for risk assessment tools that can be combined with family history (FH) to stratify disease risk among men in the general population. Since 2007, genome-...
Autores principales: | Helfand, Brian T, Kearns, James, Conran, Carly, Xu, Jianfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955171/ https://www.ncbi.nlm.nih.gov/pubmed/27297129 http://dx.doi.org/10.4103/1008-682X.182981 |
Ejemplares similares
-
Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases
por: Na, Rong, et al.
Publicado: (2016) -
A comparison of genetic risk score with family history for estimating prostate cancer risk
por: Helfand, Brian T
Publicado: (2016) -
Assessing the clinical utility of genetic risk scores for targeted cancer screening
por: Conran, Carly A., et al.
Publicado: (2021) -
Population-standardized genetic risk score: the SNP-based method of
choice for inherited risk assessment of prostate cancer
por: Conran, Carly A, et al.
Publicado: (2016) -
Personalized prostate cancer care: from screening to treatment
por: Conran, Carly A, et al.
Publicado: (2016)